文献速递淋巴瘤

霍奇金淋巴瘤中Reed-Sternberg细胞PIM激酶表达促进免疫豁免与肿瘤细胞存活

Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
PubMed 文献 · Blood · 2017-07-11

本研究探讨经典霍奇金淋巴瘤(cHL)中PIM1/2/3激酶在Reed-Sternberg(RS)细胞免疫豁免和存活中的作用。PIM1/2/3在原代和培养RS细胞中普遍表达,由JAK-STAT和NFκB活性驱动;pan-PIM抑制剂SEL24-B489诱导RS细胞凋亡,在cHL异种移植模型中使肿瘤生长延迟95.8%(P = .0002),并降低galectin-1和PD-L1/2等免疫抑制分子表达,共培养中经SEL24-B489处理的RS细胞使T细胞活化标志物表达高于对照RS细胞。作者认为PIM激酶是cHL有前景的治疗靶点。

要点

  • PIM1/2/3在原代和培养RS细胞中普遍表达,由JAK-STAT和NFκB活性驱动。
  • pan-PIM抑制剂SEL24-B489诱导RS细胞凋亡,在cHL异种移植模型中使肿瘤生长延迟95.8%(P = .0002)。
  • SEL24-B489降低galectin-1和PD-L1/2等免疫抑制分子表达,共培养中T细胞活化标志物表达高于对照。

核心结论

  • cHL中PIM激酶发挥多效作用,协调肿瘤免疫逃逸并支持RS细胞存活。
  • 抑制PIM激酶降低RS细胞活力并破坏其与微环境连接的信号回路。
  • 作者认为PIM激酶是cHL有前景的治疗靶点。

研究设计与样本

  • 研究检测了cHL中PIM1/2/3的表达,并评估其在RS细胞免疫豁免和存活中的作用。
  • 使用新开发的pan-PIM抑制剂SEL24-B489进行遗传或化学PIM抑制。
  • 在cHL异种移植模型中评估SEL24-B489对肿瘤生长的影响。
  • 进行共培养实验,比较经SEL24-B489处理的RS细胞与对照RS细胞对T细胞活化标志物表达的影响。

主要发现

  • PIM1/2/3在原代和培养RS细胞中普遍表达,其表达由JAK-STAT和NFκB活性驱动。
  • 遗传或化学PIM抑制(SEL24-B489)诱导RS细胞凋亡。
  • PIM抑制降低帽依赖蛋白翻译,阻断JAK-STAT信号,并显著减弱NFκB依赖基因表达。
  • 在cHL异种移植模型中,SEL24-B489使肿瘤生长延迟95.8%(P = .0002)。
  • SEL24-B489降低galectin-1和PD-L1/2等多种参与免疫抑制微环境形成的分子表达;共培养中经SEL24-B489处理的RS细胞使T细胞活化标志物表达高于对照RS细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reed-Sternberg (RS) cells of classical Hodgkin lymphoma (cHL) express multiple immunoregulatory proteins that shape the cHL microenvironment and allow tumor cells to evade immune surveillance. Expression of certain immunoregulatory proteins is modulated by prosurvival transcription factors, such as NFκB and STATs. Because these factors also induce expression of the oncogenic PIM1/2/3 serine/threonine kinases, and as PIMs modulate transcriptional activity of NFκB and STATs, we hypothesized that these kinases support RS cell survival and foster their immune privilege. Here, we investigated PIM1/2/3 expression in cHL and assessed their role in developing RS cell immune privilege and survival. PIM1/2/3 were ubiquitously expressed in primary and cultured RS cells, and their expression was driven by JAK-STAT and NFκB activity. Genetic or chemical PIM inhibition with a newly developed pan-PIM inhibitor, SEL24-B489, induced RS cell apoptosis. PIM inhibition decreased cap-dependent protein translation, blocked JAK-STAT signaling, and markedly attenuated NFκB-dependent gene expression. In a cHL xenograft model, SEL24-B489 delayed tumor growth by 95.8% (P = .0002). Furthermore, SEL24-B489 decreased the expression of multiple molecules engaged in developing the immunosuppressive microenvironment, including galectin-1 and PD-L1/2. In coculture experiments, T cells incubated with SEL24-B489-treated RS cells exhibited higher expression of activation markers than T cells coincubated with control RS cells. Taken together, our data indicate that PIM kinases in cHL exhibit pleiotropic effects, orchestrating tumor immune escape and supporting RS cell survival. Inhibition of PIM kinases decreases RS cell viability and disrupts signaling circuits that link these cells with their niches. Thus, PIM kinases are promising therapeutic targets in cHL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Szydłowski M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, et al. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017. PMID: 28698206. doi:10.1182/blood-2017-01-760702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。